WO2021047525A1 - Sel d'un composé de benzothiopyrone, son procédé de préparation et son utilisation - Google Patents
Sel d'un composé de benzothiopyrone, son procédé de préparation et son utilisation Download PDFInfo
- Publication number
- WO2021047525A1 WO2021047525A1 PCT/CN2020/114126 CN2020114126W WO2021047525A1 WO 2021047525 A1 WO2021047525 A1 WO 2021047525A1 CN 2020114126 W CN2020114126 W CN 2020114126W WO 2021047525 A1 WO2021047525 A1 WO 2021047525A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclohexylmethyl
- piperazin
- nitro
- benzothiopyran
- trifluoromethyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- -1 benzothiopyrone compound Chemical class 0.000 title claims abstract description 9
- LKTGKSLRRVEZFI-UHFFFAOYSA-N 2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)thiochromen-4-one Chemical compound C1(CCCCC1)CN1CCN(CC1)C=1SC2=C(C(C=1)=O)C=C(C=C2[N+](=O)[O-])C(F)(F)F LKTGKSLRRVEZFI-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 20
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 76
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 229940049920 malate Drugs 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- DHSYDTXGFJPXKA-UHFFFAOYSA-N thiochromen-4-one Chemical compound C1=CC=C2C(=O)C=CSC2=C1 DHSYDTXGFJPXKA-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 229940079593 drug Drugs 0.000 abstract description 18
- 201000008827 tuberculosis Diseases 0.000 abstract description 17
- 238000001727 in vivo Methods 0.000 abstract description 12
- 238000000338 in vitro Methods 0.000 abstract description 8
- 230000001355 anti-mycobacterial effect Effects 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 201000010099 disease Diseases 0.000 description 21
- 229940125904 compound 1 Drugs 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 230000002365 anti-tubercular Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000035699 permeability Effects 0.000 description 6
- SMCZVGWSWSDJPV-UHFFFAOYSA-N 2h-thiochromene 1-oxide Chemical class C1=CC=C2S(=O)CC=CC2=C1 SMCZVGWSWSDJPV-UHFFFAOYSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 208000015355 drug-resistant tuberculosis Diseases 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960003350 isoniazid Drugs 0.000 description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000003349 alamar blue assay Methods 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940116298 l- malic acid Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BJDZBXGJNBMCAV-UHFFFAOYSA-N 2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC(C(N=2)=O)=C1SC=2N(CC1)CCN1CC1CCCCC1 BJDZBXGJNBMCAV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- GUSANBRNBREBPL-TZTIVRRBSA-N alpha-D-Ara-(1->5)-alpha-D-Ara-(1->3)-[alpha-D-Ara-(1->5)]-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->2)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)-[alpha-D-Man-(1->2)]-alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-alpha-D-Man Chemical compound OC[C@H]1O[C@H](OC[C@H]2O[C@H](O[C@H]3[C@H](O)[C@@H](OC[C@H]4O[C@H](OC[C@H]5O[C@H](O[C@H]6[C@@H](O)[C@H](O)[C@@H](CO[C@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]7O)O[C@@H]6OC[C@H]6O[C@H](OC[C@H]7O[C@H](OC[C@H]8O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H](O)[C@@H]7O)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)O[C@@H]3CO[C@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O GUSANBRNBREBPL-TZTIVRRBSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VNXUJPCYZSNXDG-UHFFFAOYSA-N thiopyran-4-one Chemical compound O=C1C=CSC=C1 VNXUJPCYZSNXDG-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Definitions
- the invention belongs to the field of medical technology.
- it relates to salts of benzothiopyrone compounds: 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8 represented by formula (I) -Nitro-benzothiopyran-4-one salt, its preparation method, pharmaceutical composition using the salt as an active ingredient, and their preparation for the treatment and/or prevention of infectivity caused by Mycobacterium tuberculosis Application of disease drugs.
- Tuberculosis (Tuberculosis, TB) is a chronic fatal disease caused by Mycobacterium tuberculosis. It is a major infectious disease that endangers human health and causes human death. According to WHO estimates, there were approximately 1.7 billion people latently infected with tuberculosis worldwide in 2017, and the latent infection rate was 23%. There are about 10 million new cases of tuberculosis in the world, and about 1.4 million deaths. The incidence of tuberculosis is 133 per 100,000. Among them, children younger than 15 years old and HIV-infected people account for 10% and 9% of the new cases, respectively.
- the unique cell wall of Mycobacterium tuberculosis has a multi-layered structure.
- the biosynthetic pathways of these unique components are a rich source of potential drug targets.
- the first-line drugs isoniazid and ethambutol act on mycolic acid and arabinan layers, respectively. Synthesis, interferes with the formation of the cell wall of Mycobacterium tuberculosis.
- the main component of the arabinogalactan layer and arabinomannan layer of the outer membrane of Mycobacterium tuberculosis cell wall is a kind of arabinose with DPA as an important precursor. Studies have shown that DPA is mainly composed of DPR in DprE1 and DprE2.
- Epimerization is obtained under the joint action, so inhibiting the activity of DprE1 can hinder the synthesis of cell wall and ultimately achieve the purpose of killing Mycobacterium tuberculosis two-step epimerization of decaprenylphosphoryl ribose. Journal of bacteriology 2005,187(23),8020-8025).
- the benzothiopyrone core structure has been determined as the dominant skeleton and applied for Patent (Patent No.: 201810092333.X and PCT/CN2018/080787), through systematic and in-depth research, obtained the benzothiopyrone compound 6b(2) with significant anti-tuberculosis and drug-resistant tuberculosis activity and low toxicity -(4-(Cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro-benzothiopyran-4-one)(Identification of novel benzothiopyranone compounds against against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones[J].Eur.J.Med.Chem.,2018,160,157-170).
- Patent 201810092333.X and PCT/CN2018/080787 disclose 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro-benzothiopyridine Examples of pyran-4-one and its hydrochloride salt, but no specific examples and experimental results of other pharmaceutically acceptable salts are disclosed.
- the technical problem to be solved by the present invention is to provide a 2-(4-(cyclohexylmethyl)piperazin-1-yl) which has significantly improved pharmacokinetic properties and physical and chemical properties and has strong activity against Mycobacterium tuberculosis in vivo and in vitro.
- Salt of 6-(trifluoromethyl)-8-nitro-benzothiopyran-4-one The present invention found that the salt of 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro-benzothiopyran-4-one has Strong anti-Mycobacterium tuberculosis effect in vivo and in vitro.
- the present invention provides the following technical solutions:
- the first aspect of the technical scheme of the present invention provides 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro-benzo represented by formula (I)
- salt of 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro-benzothiopyran-4-one does not include salt Acid salt.
- the salt of any one of the first aspect of the present invention is characterized in that it is 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro-
- the maleate, fumarate, citrate and L-malate of benzothiopyran-4-one is 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro- The maleate, fumarate, citrate and L-malate of benzothiopyran-4-one.
- the salt of any one of the first aspect of the present invention is characterized in that it is 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro- Benzothiopyran-4-one ⁇ 1 maleate, 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro- Benzothiopyran-4-one 1/2 maleate, 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8-nitro -Benzothiopyran-4-one ⁇ 3/2 maleate; 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8 -Nitro-benzothiopyran-4-one ⁇ 1 fumarate, 2-(4-(cyclohexylmethyl)piperazin-1-yl)-6-(trifluoromethyl)-8 -N
- the second aspect of the technical solution of the present invention provides a method for preparing the salt according to the first aspect of the present invention, which comprises the following steps:
- the third aspect of the technical solution of the present invention provides a pharmaceutical composition, which comprises a therapeutically and/or preventively effective amount of a pharmaceutically acceptable salt of the compound according to the first aspect of the present invention, and optionally one or A variety of pharmaceutically acceptable carriers, excipients, diluents, excipients and vehicles.
- the fourth aspect of the technical solution of the present invention provides a pharmaceutically acceptable salt of the compound of the first aspect of the present invention, or the pharmaceutical composition of the third aspect of the present invention is used in the preparation of treatment and/or prevention caused by Mycobacterium tuberculosis Application of medicines for infectious diseases.
- room temperature refers to a temperature from 10°C to 40°C. In some embodiments, “room temperature” refers to a temperature from 20°C to 30°C; in other embodiments, room temperature refers to 25°C.
- the term "effective amount” refers to the amount of a drug that can achieve the desired treatment of the disease or condition of the present invention in a subject.
- the term "pharmaceutically acceptable”, for example, when describing “pharmaceutically acceptable salt”, means that the salt is not only physiologically acceptable to the subject, but also refers to a synthetic material that is of pharmaceutically useful value. substance.
- composition can also refer to a “composition”, which can be used to achieve the treatment of the disease or condition of the present invention in a subject, especially a mammal.
- the "treatment” of the disease includes:
- a “therapeutically effective amount” refers to an amount of a compound that is sufficient to achieve treatment of the disease when administered to a mammal for the treatment of the disease.
- the therapeutically effective amount will vary depending on the compound, the disease to be treated and its severity, and the mammal's age, weight, sex and other factors.
- a therapeutically effective amount can also refer to any amount of the compound sufficient to achieve the desired beneficial effect, including the prevention, suppression or alleviation of diseases as described in (1)-(3) above.
- the amount of compound may be between 0.1-250 mg/kg, or preferably, 0.5-100 mg/kg, or more preferably, 1-50 mg/kg, or even more preferably, 2-20 mg/kg.
- the amount of the compound is administered to the mammal twice a day. More preferably, the amount of the compound is administered to the mammal once a day.
- the term "disease and/or disorder” refers to a physical state of the subject, which physical state is related to the disease and/or disorder described in the present invention.
- the diseases and/or conditions described in the present invention refer to infectious diseases of Mycobacterium tuberculosis.
- the term "subject” may refer to a patient or other animal, particularly a mammal, that receives a salt of the compound of formula (I) of the present invention or a pharmaceutical composition thereof to treat the disease or condition of the present invention, for example People, dogs, monkeys, cows, horses, etc.
- Another aspect of the present invention also relates to a pharmaceutical composition using the compound of the present invention as an active ingredient.
- the pharmaceutical composition can be prepared according to methods known in the art.
- the compound of the present invention can be combined with one or more pharmaceutically acceptable solid or liquid excipients and/or adjuvants to prepare any dosage form suitable for human or animal use.
- the compound of the present invention or the pharmaceutical composition containing it can be administered in unit dosage form, and the route of administration can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous injection, nasal cavity, oral mucosa, eye, Lung and respiratory tract, skin, vagina, rectum, etc.
- the dosage form for administration may be a liquid dosage form, a solid dosage form or a semi-solid dosage form.
- Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o/w type, w/o type and double emulsion), suspensions, injections (including water injections, powder injections and infusions), eye drops
- the solid dosage form can be tablets (including ordinary tablets, enteric-coated tablets, buccal tablets, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules ( Including hard capsules, soft capsules, enteric-coated capsules), granules, powders, pellets, dripping pills, suppositories, films, patches, aerosols, sprays, etc.; semi-solid dosage forms can be ointments, Gels, pastes, etc.
- the compound of the present invention can be made into ordinary preparations, and can also be made into sustained-release preparations, controlled-release preparations, targeted preparations and various particulate drug delivery systems.
- diluents can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.
- wetting agent can be water, ethanol, Isopropanol, etc.
- the binder can be starch syrup, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia syrup, gelatin syrup, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl Methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.
- the disintegrant can be dry starch, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.
- the wetting agent can be water, ethanol, Isopropanol, etc.
- the binder can be starch syrup, de
- the tablets can also be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
- the active ingredient of the compound of the present invention can be mixed with a diluent and a co-solvent, and the mixture can be directly placed in a hard or soft capsule.
- the active ingredient of the compound of the present invention can also be prepared into granules or pellets with diluents, binders, and disintegrants, and then placed in hard or soft capsules.
- the various diluents, binders, wetting agents, disintegrants, and cosolvents used to prepare the compound tablets of the present invention can also be used to prepare the compound capsules of the present invention.
- solubilizers, cosolvents, pH regulators, and osmotic pressure regulators commonly used in this field can be added.
- the solubilizer or co-solvent can be poloxamer, lecithin, hydroxypropyl- ⁇ -cyclodextrin, etc.
- the pH regulator can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.
- the osmotic pressure regulator can be It is sodium chloride, mannitol, glucose, phosphate, acetate, etc.
- mannitol, glucose, etc. can also be added as proppants.
- coloring agents can also be added to the pharmaceutical preparations.
- the drug or pharmaceutical composition of the present invention can be administered by any known administration method.
- the compound or composition of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs.
- the compound of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.
- the inventor of the present invention synthesized the salt of the compound represented by formula (I), and performed the minimum inhibitory concentration (MIC ) with M. tuberculosis H 37 Rv strain by the MABA (Microplate alamar blue assay) method.
- the test showed strong anti-Mycobacterium tuberculosis activity.
- 5 salts with MIC ⁇ 0.016 ⁇ g/mL were obtained, which was significantly stronger than isoniazid, the first-line anti-tuberculosis drug.
- the maleate, fumarate, citrate and L-malate of the compound of formula (I) of the present invention are superior to the hydrochloride of the compound of formula (I) in cell permeability, indicating that the present invention Salt has better absorption properties.
- mice showed that the bioavailability of the maleate and L-malate of the compound of formula (I) was significantly improved compared to that of the compound (I).
- the results of rat pharmacokinetic experiments showed that compared with the compound of formula (I) and its hydrochloride, the maleate of the compound of formula (I) has significantly increased in vivo exposure (AUC) and bioavailability, which indicates that the present invention
- the salt has better pharmacokinetic properties than the free base and hydrochloride.
- In vivo pharmacodynamic experiments in mice showed that the maleate of the compound of formula (I) has stronger anti-tuberculosis activity in vivo than the compound of formula (I) at the same dose.
- the test results of influencing factors show that the maleate of the compound of formula (I) is very stable when placed under light, high temperature and high humidity conditions for ten days, especially under light conditions, the stability is significantly better than that of compound (I), which indicates
- the salt of the invention has a significant improvement in light stability.
- the present invention provides a class of salts of benzothiopyrone compounds with strong anti-tuberculosis activity, significantly improved pharmacokinetic properties and physical and chemical properties, which can be used for infectious diseases caused by bacteria, especially tuberculosis branches.
- the treatment or preventive treatment of tuberculosis caused by bacilli can also be used to overcome the problems related to drug resistance.
- the structure of the compound was determined by proton nuclear magnetic resonance spectroscopy ( 1 H NMR).
- the chemical shift ( ⁇ ) of the proton nuclear magnetic resonance spectrum is given in units of parts per million (ppm).
- the coupling constant (J) is in Hertz (Hz).
- the NMR spectrum was measured with a Mercury-400 nuclear magnetic resonance instrument, deuterated methanol (CD 3 OD) and deuterated dimethyl sulfoxide (DMSO-d 6 ) were used as solvents, and tetramethylsilane (TMS) was used as an internal standard.
- the electronic balance adopts the Japanese Yanaco LY-300 electronic balance.
- Anhydrous solvents are processed by standard methods.
- Other reagents are commercially available analytical grade.
- CFU is the colony forming unit
- MIC is the minimum inhibitory concentration
- iv is intravenous administration
- AUC is the area under the drug concentration-time curve
- T max is the peak time
- MABA Microplate Alamar Blue Assay
- Alamar Blue added to the culture medium can be used as a redox indicator, and the color changes from blue to red, reflecting the consumption of oxygen molecules by the studied microorganisms.
- the color change of Alamar Blue can be measured with a photometer, and its emission wavelength is 590nm.
- Caco-2 cells are human cloned colon adenocarcinoma cells, similar in structure and function to differentiated epithelial cells, with microvilli and other structures, and are widely used in vitro to simulate the penetration and absorption of drugs in the intestinal tract.
- the apparent permeability coefficient (Papp) of the compound is calculated by the following formula:
- dQ/dt is the permeation rate of drug molecules across the membrane
- C 0 is the initial concentration of the drug
- A is the area of the monolayer.
- mice Male weighing 23-25 grams were used in each group for the pharmacokinetic study of compounds 1, 2, 3 and 5.
- Compounds 1, 2, 3 and 5 were prepared as 5 mg/mL suspensions with 0.5% carboxymethyl cellulose, respectively, and were administered orally at a dose of 50 mg/kg.
- Compounds 1, 2, 3 and 5 were prepared as 1 mg/mL solutions with 20% HP- ⁇ -CD and 1N hydrochloric acid, respectively, and were given a dose of 5 mg/kg intravenously.
- Plasma samples were collected at 5, 15, 30 minutes, and 1, 2, 4, 7, and 24 hours after oral and intravenous administration. The collected plasma samples are stored at -80°C until used for analysis. Plasma samples were extracted with acetonitrile containing terfenadine internal standard, and the ratio of extractant to plasma was 20:1.
- the analyte was quantified by LC/TSQ Quantum Access mass spectrometer (AB Sciex5500). Chromatographic conditions: Column: Kinetex C18 100A (30mm ⁇ 3.0mm, 2.6 ⁇ m); column temperature: room temperature, mobile phase: acetonitrile/water (80:20, v/v) (containing 0.1% formic acid); flow rate: 0.8mL /min.
- the compound detection on the mass spectrometer is carried out in electrospray positive ionization mode.
- the WinNonlin software (6.3Pharsight Corporation, Mountain View, USA) was used to calculate the pharmacokinetic parameters.
- the bioavailability (F) of the compounds 1, 2, 3 and 5 of the present invention is 18.9-28.0%.
- the bioavailability of the free base 6b (compound (I)) of compounds 1, 2, 3 and 5 reported in the comparative document (Eur. J. Med. Chem., 2018, 160, 157-170) is 13.1%.
- the bioavailability of compounds 1, 2, 3 and 5 is improved, among which compounds 1 and 5 are increased by about 1 times, indicating that the compound of the present invention has better pharmacokinetic properties.
- Compound 1 Compound (I) and its hydrochloride were prepared into a 5 mg/mL suspension with 0.5% carboxymethyl cellulose, respectively, and were administered orally at a dose of 50 mg/kg.
- HP- ⁇ -CD hydroxypropyl- ⁇ -cyclodextrin
- Plasma samples were collected 5, 15, 30 minutes after oral and intravenous administration, and 1, 2, 4, 7, 12, and 24 hours. The collected plasma samples are stored at -80°C until used for analysis. The WinNonlin software (6.3Pharsight Corporation, Mountain View, USA) was used to calculate the pharmacokinetic parameters.
- Balb/c mice were infected with Mycobacterium tuberculosis H37Rv by aerosol, and were given drug treatment (25, 50, 100 mg/kg) 10 days after infection, once a day, 5 times a week, three weeks after the administration, Anatomy, with the lung CFU as the main evaluation index, a blank control group was set up to give 0.5% CMC, and the first-line clinical drug isoniazid was used as the positive control drug to investigate the anti-tuberculosis activity of compound (I) and compound 1 in vivo.
- the CMC group is a blank control group, given 0.5% CMC.
- test results show that compound (I) has strong anti-tuberculosis activity at doses of 25, 50 and 100 mg/kg, and the number of viable lung tissues in mice decreased by 2.28, 3.58 and 3.73 log 10 CFU respectively compared with the blank control group.
- the CMC group is a blank control group, given 0.5% CMC.
- test results show that compound 1 has strong anti-tuberculosis activity at doses of 25, 50 and 100 mg/kg, and shows a significant dose-effect relationship.
- the number of viable lung tissues in mice decreased by 3.01, respectively, compared with the blank control group. 3.99 and 4.68 log 10 CFU.
- compound 1 of the present invention can reduce Log 10 CFU values more than compound (I) at doses of 25, 50 and 100 mg/kg, especially at doses of 100 mg/kg. Compared with the blank control group, compound 1 can reduce 4.68 Log 10 CFU, which is significantly better than compound (I) (reducing 3.73 Log 10 CFU), indicating that compound 1 has stronger anti-tuberculosis activity in vivo.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention relève du domaine technique de la médecine, et concerne un sel d'un composé de benzothiopyrone, son procédé de préparation et son utilisation, en particulier, un sel de 2-(4-(cyclohexylméthyl)pipérazin-1-yl)-6-(trifluorométhyl)-8-nitro-benzothiopyran-4-one tel que représenté par la formule (I), son procédé de préparation, une composition pharmaceutique de celui-ci, et une utilisation associée dans la préparation d'un médicament pour le traitement et/ou la prévention d'une maladie infectieuse provoquée par Mycobacterium tuberculosis. La présente invention vise à préparer un sel de 2-(4-(cyclohexylméthyl)pipérazin-1-yl)-6-(trifluorométhyl)-8-nitro-benzothiopyran-4-one ayant des propriétés pharmacocinétiques et physico-chimiques significativement améliorées et ayant une forte activité contre Mycobacterium tuberculosis in vivo et in vitro ; en tant que nouveau médicament potentiel, le sel peut être utilisé pour le traitement ou le traitement préventif d'une maladie infectieuse provoquée par des bactéries, en particulier la tuberculose (TB) provoquée par Mycobacterium tuberculosis, et peut également être utilisé pour surmonter un problème lié à la résistance aux médicaments de Mycobacterium tuberculosis.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080070377.8A CN114929682B (zh) | 2019-09-09 | 2020-09-09 | 苯并硫代吡喃酮类化合物的盐及其制备方法和用途 |
ZA2022/03673A ZA202203673B (en) | 2019-09-09 | 2022-03-30 | Salt of benzothiopyrone compound, and preparation method therefor and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910849215.3A CN112457291B (zh) | 2019-09-09 | 2019-09-09 | 苯并硫代吡喃酮类化合物的盐及其制备方法和用途 |
CN201910849215.3 | 2019-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021047525A1 true WO2021047525A1 (fr) | 2021-03-18 |
Family
ID=74807398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/114126 WO2021047525A1 (fr) | 2019-09-09 | 2020-09-09 | Sel d'un composé de benzothiopyrone, son procédé de préparation et son utilisation |
Country Status (3)
Country | Link |
---|---|
CN (2) | CN112457291B (fr) |
WO (1) | WO2021047525A1 (fr) |
ZA (1) | ZA202203673B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4296674A1 (fr) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Molécules innovantes réduisant la virulence des mycobactéries pour le traitement de la tuberculose |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49101379A (fr) * | 1973-02-05 | 1974-09-25 | ||
CN104211708A (zh) * | 2013-05-29 | 2014-12-17 | 中国医学科学院药物研究所 | 苯并噁嗪酮衍生物及其作为抗菌剂的应用 |
CN108929329A (zh) * | 2017-05-24 | 2018-12-04 | 中国医学科学院药物研究所 | 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物 |
CN108947952A (zh) * | 2017-05-24 | 2018-12-07 | 中国医学科学院药物研究所 | 2-取代氨基-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物及其制备方法和用途 |
-
2019
- 2019-09-09 CN CN201910849215.3A patent/CN112457291B/zh active Active
-
2020
- 2020-09-09 WO PCT/CN2020/114126 patent/WO2021047525A1/fr active Application Filing
- 2020-09-09 CN CN202080070377.8A patent/CN114929682B/zh active Active
-
2022
- 2022-03-30 ZA ZA2022/03673A patent/ZA202203673B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49101379A (fr) * | 1973-02-05 | 1974-09-25 | ||
CN104211708A (zh) * | 2013-05-29 | 2014-12-17 | 中国医学科学院药物研究所 | 苯并噁嗪酮衍生物及其作为抗菌剂的应用 |
CN108929329A (zh) * | 2017-05-24 | 2018-12-04 | 中国医学科学院药物研究所 | 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物 |
CN108947952A (zh) * | 2017-05-24 | 2018-12-07 | 中国医学科学院药物研究所 | 2-取代氨基-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
LI PENG; WANG BIN; ZHANG XINWEI; BATT SARAH M.; BESRA GURDYAL S.; ZHANG TINGTING; MA CHEN; ZHANG DONGFENG; LIN ZIYUN; LI GANG; HUA: "Identification of novel benzothiopyranone compounds againstMycobacterium tuberculosisthrough scaffold morphing from benzothiazinones", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 160, 17 September 2018 (2018-09-17), AMSTERDAM, NL, pages 157 - 170, XP085521522, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2018.09.042 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4296674A1 (fr) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Molécules innovantes réduisant la virulence des mycobactéries pour le traitement de la tuberculose |
Also Published As
Publication number | Publication date |
---|---|
CN114929682B (zh) | 2024-05-14 |
CN112457291B (zh) | 2022-07-22 |
ZA202203673B (en) | 2024-01-31 |
CN112457291A (zh) | 2021-03-09 |
CN114929682A (zh) | 2022-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
MXPA01008549A (es) | Metodos de tratamiento de desordenes mitocondriales. | |
TW201625618A (zh) | 抑制瞬時受體電位a1離子通道 | |
TW200811142A (en) | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | |
CN111635309B (zh) | 一种新型解热镇痛药物及其制备方法和用途 | |
EP3437644B1 (fr) | Composés pour utilisation dans le traitement de l'hypertension pulmonaire | |
CN113274392A (zh) | 用于治疗慢性咳嗽的奥维匹坦 | |
WO2007149285A2 (fr) | Procédé servant à améliorer la diurèse chez des individus atteints d'une détérioration de la fonction rénale | |
WO2018214639A1 (fr) | Composé de 2-azacyclo-5-trifluorométhyl-8-nitrobenzo(thio)pyran-4-one, son procédé de préparation et son utilisation | |
CN111635315B (zh) | 一种解热镇痛药物及其制备方法和用途 | |
RU2367442C2 (ru) | Способ нормализации мочеиспускания при нарушении функции почек | |
IE64285B1 (en) | 4-Quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases | |
AU2004220205B2 (en) | Antitumor effect potentiator and antitumor agent | |
JPWO2002020540A1 (ja) | アデノシン誘導体及びその用途 | |
WO2021047525A1 (fr) | Sel d'un composé de benzothiopyrone, son procédé de préparation et son utilisation | |
US11141421B2 (en) | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer | |
JP2020503366A (ja) | グローコカリキシンa誘導体、その医薬的に許容できる塩または医薬組成物、およびこれらの乾癬治療用医薬の調製における使用 | |
EP3904335A1 (fr) | Dérivé d'acide acétylsalicylique et son utilisation | |
EP4166140A1 (fr) | Agent prophylactique ou thérapeutique de traitement de la porphyrie | |
JP3450399B2 (ja) | 血管新生阻害剤 | |
JP3834089B2 (ja) | ベンズイミダゾール誘導体を含有するぜん息治療剤 | |
KR20190090729A (ko) | 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
US9745275B2 (en) | Pain-related compound and medical composition | |
US20120059020A1 (en) | Prophylactic or therapeutic agent for pulmonary fibrosis | |
CN112516121B (zh) | 包含牛磺酸和别嘌醇的组合物及其医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20862129 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022107043 Country of ref document: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20862129 Country of ref document: EP Kind code of ref document: A1 |